PK-Directed Intravenous Busulfan in Combination with High-Dose Melphalan and Bortezomib As Conditioning Regimen for Patients with Multiple Myeloma

High dose therapy followed by autologous hematopoietic stem cell transplantation (ASCT) has an established role in the treatment of patients with multiple myeloma (MM). The CR rate, an indicator for progression-free and overall survival (PFS; OS) observed after the most commonly used conditioning regimen Mel200 (Melphalan 200mg/m2) is between 10-35%. The objective of our trial is to assess whether conditioning with a combination of PK-directed Busulfan (Bu), Mel and Bortezomib (Btz) is safe and can improve CR rates in patients with MM.